Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A review on the role of cyclin dependent kinases in cancers
Soudeh Ghafouri‐Fard, Tayyebeh Khoshbakht, Bashdar Mahmud Hussen, et al.
Cancer Cell International (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 70

Showing 1-25 of 70 citing articles:

Cyclin-dependent kinase 2 (CDK2) inhibitors and others novel CDK inhibitors (CDKi) in breast cancer: clinical trials, current impact, and future directions
R. Gerosa, Rita De Sanctis, Flavia Jacobs, et al.
Critical Reviews in Oncology/Hematology (2024) Vol. 196, pp. 104324-104324
Open Access | Times Cited: 15
Targeting DNA repair for cancer treatment: Lessons from PARP inhibitor trials
Dhanya K. Nambiar, Deepali Mishra, Rana P. Singh
Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics (2023) Vol. 31, Iss. 4, pp. 405-421
Open Access | Times Cited: 26
Quiescent Cancer Cells—A Potential Therapeutic Target to Overcome Tumor Resistance and Relapse
Emma Lindell, Lei Zhong, Xiaonan Zhang
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 4, pp. 3762-3762
Open Access | Times Cited: 23
Hepatocellular Carcinoma: Old and Emerging Therapeutic Targets
Greta Pessino, Claudia Scotti, Maristella Maggi
Cancers (2024) Vol. 16, Iss. 5, pp. 901-901
Open Access | Times Cited: 9
Design, synthesis, antineoplastic activity of new pyrazolo[3,4-d]pyrimidine derivatives as dual CDK2/GSK3β kinase inhibitors; molecular docking study, and ADME prediction
Mohamed T. M. Nemr, Ahmed Elshewy, Mohammed L. Ibrahim, et al.
Bioorganic Chemistry (2024) Vol. 150, pp. 107566-107566
Closed Access | Times Cited: 9
Elucidating the Mechanisms of Acquired Palbociclib Resistance via Comprehensive Metabolomics Profiling
Lulu Yang, Yajun Yue, Zhendong Wang, et al.
Current Issues in Molecular Biology (2025) Vol. 47, Iss. 1, pp. 24-24
Open Access
Is there a pathological switch that triggers the onset of renal calcification?
Thamarasee Jeewandara
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
Post-Translational Modifications of Proteins Orchestrate All Hallmarks of Cancer
Pathea Bruno, Aneeta Arshad, Maria-Raluca Gogu, et al.
Life (2025) Vol. 15, Iss. 1, pp. 126-126
Open Access
Multitarget CDK inhibitors roscovitine and UCN‑01 induce apoptosis in colorectal cancer cells by inhibiting cell cycle progression and transcription
Sonal M. Manohar, Kalpana Joshi
Brazilian Journal of Pharmaceutical Sciences (2025) Vol. 61
Open Access
Positively charged specificity site in cyclin B1 is essential for mitotic fidelity
Christian Heinzle, Anna Höfler, Jun Yu, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access
Gintonin-Enriched Panax ginseng Extract Induces Apoptosis in Human Melanoma Cells by Causing Cell Cycle Arrest and Activating Caspases
S. Lee, Gyun-Seok Park, Rami Lee, et al.
Foods (2025) Vol. 14, Iss. 3, pp. 381-381
Open Access
Discovery of KB-0742, a Potent, Selective, Orally Bioavailable Small Molecule Inhibitor of CDK9 for MYC-Dependent Cancers
David B. Freeman, Tamara D. Hopkins, Peter Mikochik, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 23, pp. 15629-15647
Open Access | Times Cited: 16
A comprehensive review of the anticancer effects of decursin
Yueming Chu, Qiang Yuan, Hangyu Jiang, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 4
Discovery of macrocyclic CDK2/4/6 inhibitors with improved potency and DMPK properties through a highly efficient macrocyclic drug design platform
Fanye Meng, Jinxin Liu, Zhongying Cao, et al.
Bioorganic Chemistry (2024) Vol. 146, pp. 107285-107285
Closed Access | Times Cited: 4
Effects of super-enhancers in cancer metastasis: mechanisms and therapeutic targets
Shenglan Liu, Wei Dai, Bei Jin, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 4
CircNCOR1 regulates breast cancer radiotherapy efficacy by regulating CDK2 via hsa-miR-638 binding
Zhen-Yu He, Rengong Zhuo, Shi‐Ping Yang, et al.
Cellular Signalling (2023) Vol. 109, pp. 110787-110787
Closed Access | Times Cited: 12
Imidazopyridine-based kinase inhibitors as potential anticancer agents: A review
Fariba Peytam, Zahra Emamgholipour, Ali Mousavi, et al.
Bioorganic Chemistry (2023) Vol. 140, pp. 106831-106831
Closed Access | Times Cited: 10
Lycopene suppresses gastric cancer cell growth without affecting normal gastric epithelial cells
Ying Zhou, Rishun Fu, Mei Yang, et al.
The Journal of Nutritional Biochemistry (2023) Vol. 116, pp. 109313-109313
Closed Access | Times Cited: 8
In vitro cell-transforming potential of secondary polyethylene terephthalate and polylactic acid nanoplastics
Josefa Domenech, Aliro Villacorta, Juan Francisco Ferrer, et al.
Journal of Hazardous Materials (2024) Vol. 469, pp. 134030-134030
Open Access | Times Cited: 2
Graph theoretical analysis, pharmacoinformatics and molecular docking investigation of Chalcone-Schiff base hybrids as Cyclin-Dependent kinase inhibitors
Praveen Sekar, Sathishkumar Arivanantham, Pavithra Jaishankar, et al.
Research in Pharmacy (2024)
Open Access | Times Cited: 2
Maleimide conjugated PEGylated liposomal antibiotic to combat multi-drug resistant Escherichia coli and Klebsiella pneumoniae with enhanced wound healing potential
Darshan Narendrabhai Ladva, Pradeep Pushparaj Selvadoss, Grishma Kantibhai Chitroda, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 2
Prognostic and immunological characteristics of CDK1 in lung adenocarcinoma: A systematic analysis
Qingwu Du, Wenting Liu, Ting Mei, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 5
Anti-hepatocellular carcinoma activity of the cyclin-dependent kinase inhibitor AT7519
Kaja Karaś, Iwona Karwaciak, Katarzyna Chałaśkiewicz, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 164, pp. 115002-115002
Open Access | Times Cited: 5
Identification of Hub of the Hub-Genes From Different Individual Studies for Early Diagnosis, Prognosis, and Therapies of Breast Cancer
Md Shahin Alam, Adiba Sultana, Md. Kaderi Kibria, et al.
Bioinformatics and Biology Insights (2024) Vol. 18
Open Access | Times Cited: 1
Intrinsic Resistance to Osimertinib in EGFR Mutated NSCLC Cell Lines Induced by Alteration in Cell-Cycle Regulators
Francesco Volta, Silvia La Monica, Alessandro Leonetti, et al.
Targeted Oncology (2023) Vol. 18, Iss. 6, pp. 953-964
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top